Table 1. Androgen receptor (AR) expression across malignancies.
| Malignancy | Subtype | AR positivity % (positive/tested)* | Supplementary References |
|---|---|---|---|
| Adrenocortical carcinoma | Not specified | 38% (6/16) | [S49] |
| Astrocytoma | Grade I/II | 28% (5/18) | [S89] |
| Astrocytoma | Anaplastic | 75% (3/4) | [S89] |
| Basal cell carcinoma | Not specified | 65% (20/31) – 78% (25/32) | [S34, S35] |
| Bladder cancer | Urothelial carcinoma | 12.9% (61/472) - 51% (7/139) | [S53, S55] |
| Breast cancer | Her-2 adenocarcinoma | 85.6% (89/104) | [S110] |
| Breast cancer | BRCA1 | 32% (43/135) | [S112] |
| Breast cancer | BRCA2 | 13% (18/135) | [S112] |
| Breast cancer | BRCA negative | 76% (56/74) | [S112] |
| Cervical invasive carcinoma | Squamous | 23% (3/13) | [S91] |
| Colon adenocarcinoma | Not specified | 38% (5/13) | [S80] |
| Desmoid tumors | Not specified | 52.9% (14/27) | [S85] |
| Esophageal carcinoma | Not specified | 25% (1/4) – 33% (7/21) | [S69] |
| Gastric carcinoma | Not specified | 12.5% (2/16) – 39% (46/117) | [S65, S67] |
| Glioblastoma multiformis | Not specified | 40% (4/10) | [S89] |
| Head and neck carcinoma | Laryngeal squamous | 0% - 10% (1/10) | [S26, S27] |
| Juvenile nasopharyngeal fibroma | Not specified | 38.4% (5/13) - 75% (18/24) | [S22, S23] |
| Melanoma | Not specified | 4% - 40% | [S30] |
| Meningioma | Not specified | 42% (8/19) | [S90] |
| Non-small cell lung cancer | Not specified | 31% (20/64) - 70.5% (12/17) | [S62, S63] |
| Ovarian cancer | Epithelial | 18% (28/154) – 27% (7/26) | [S101, S105] |
| Ovarian cancer | Steroid cell tumors | 64% (9/14) | [S100] |
| Pancreatic adenocarcinoma | Not specified | 0% (0/12) | [S72] |
| Peritoneal mesothelioma | Not specified | 65% | [55] |
| Prostate cancer | Not specified | 95% | [S58] |
| Testicular germ cell | Seminoma | 45% | [S44] |
| Thymic carcinoma | Not specified | 0% (0/12) | [S19] |
| Thymoma | B3 thymoma | 58.8% (10/17) | [S19] |
| Thyroid carcinoma | Papillary | 79% - 80% (4/5) | [S11, 56] |
| Thyroid carcinoma | Follicular | 14% (4/28) | [S11] |
| Thyroid carcinoma | Medullary | 2% - 14% (4/28) | [S11, S12] |
| Thyroid carcinoma | Anaplastic | 1% | [S11] |
| Rectal adenocarcinoma | Not specified | 39% (9/23) | [S80] |
| Renal cancer | Not specified | 14.8% (27/82) – 42% (5/12) | [S45, S46] |
| Salivary gland | Pleomorphic adenoma | 4.8% (2/41) – 100% (14/14) | [S2] |
| Salivary gland | Salivary duct carcinoma | 92% (11/12) – 100% (6/6) | [S1, S2, S4-S6] |
| Salivary gland | Mucoepidermoid carcinoma | 6.6% (2/30) - 20% (2/10) | [S2] |
| Salivary gland | Adenoid cystic carcinoma | 0% (0/8) – 20% (2/10) | [S2] |
| Sarcoma | Kaposi | 0% (0/22) | [S42] |
| Sarcoma | Osteosarcoma | 28.5% (8/28) – 50.8% (33/65) | [S36, S37] |
| Uterine sarcoma | Leiomyosarcoma | 0% (0/28) – 40% (10/25) | [S95, S97] |
| Uterine sarcoma | Endometrial stromal | 45% (9/20) | [S96] |
| Uterine carcinoma | Endometrial carcinoma | 16% (4/25) - 88.6% (39/44) | [S93, S94] |
*
Numerators and denominators in the third column were given when they were clearly defined in the references.